{"article_title": "Karen Ignagni: Paying for the Thousand-Dollar Pill", "article_keywords": ["paying", "plans", "karen", "system", "specialty", "thousanddollar", "vital", "various", "negotiations", "prices", "health", "treatments", "soaring", "pill", "ignagni"], "article_url": "http://www.wsj.com/articles/karen-ignagni-paying-for-the-thousand-dollar-pill-1407099169", "article_text": "Every day across the country, health plans are in negotiations with doctors, hospitals and device and drug manufacturers. The negotiations concern the prices of various treatments, with health plans aiming to make it possible for consumers to gain access to the highest-quality care at the lowest cost. This interplay is fundamental to a market-based health-care system and it is vital to delivering affordable coverage options.\n\nLately, there has been considerable debate about the soaring prices of specialty drugs, which are...", "article_metadata": {"article.template": "snippet", "article.created": "2014-08-03T20:52:00.000Z", "article.section": "Opinion", "page.region": "na,us", "page.content.type": "Article", "twitter": {"domain": "wsj.com", "description": "In The Wall Street Journal, Karen Ignagni writes that specialty drugs account for 25% of U.S. drug costs. Health plans need to know more about them.", "title": "Paying for the Thousand-Dollar Pill", "image": {"src": "https://si.wsj.net/public/resources/images/BN-DY408_edp080_G_20140803115310.jpg", "alt": "Karen Ignagni: Paying for the Thousand-Dollar Pill", "identifier": "https://si.wsj.net/public/resources/images/BN-DY408_edp080_D_20140803115310.jpg"}, "site": "@WSJ", "card": "summary_large_image"}, "al": {"ios": {"url": "wsj://launch?articleid=SB10001424052702303635604580061443794995892&headline=Karen%20Ignagni%3A%20Paying%20for%20the%20Thousand-Dollar%20Pill&weburl=http://www.wsj.com/articles/SB10001424052702303635604580061443794995892"}}, "page.site.product": "WSJ", "keywords": "CVS Caremark,CVS,marketing,pricing,corporate,industrial news,advice,commentaries,opinions,biotechnology,pharmaceuticals,health care,life sciences,drug discovery,development", "news_keywords": "CVS Caremark,CVS,marketing,pricing,corporate,industrial news,advice,commentaries,opinions,biotechnology", "article.headline": "Karen Ignagni: Paying for the Thousand-Dollar Pill", "cXenseParse": {"candybar": {"image": "https://si.wsj.net/public/resources/images/BN-DY408_edp080_E_20140803115310.jpg"}, "poptart": {"image": "https://si.wsj.net/public/resources/images/BN-DY408_edp080_D_20140803115310.jpg"}}, "description": "In The Wall Street Journal, Karen Ignagni writes that specialty drugs account for 25% of U.S. drug costs. Health plans need to know more about them.", "apple-itunes-app": "app-id=364387007,app-argument=wsj://launch?articleid=SB10001424052702303635604580061443794995892&headline=Karen%20Ignagni%3A%20Paying%20for%20the%20Thousand-Dollar%20Pill&weburl=http://www.wsj.com/articles/SB10001424052702303635604580061443794995892", "user.type": "nonsubscriber", "testkeys": "C", "article.page": "Opinion", "article.summary": "In The Wall Street Journal, Karen Ignagni writes that specialty drugs account for 25% of U.S. drug costs. Health plans need to know more about them.", "page.site": "wsj", "page.content.format": "responsive", "article.published": "2014-08-03T20:52:00.000Z", "dj.asn": "i-e968", "robots": "noarchive,noodp", "fb": {"app_id": 368513495882}, "article": {"publisher": "https://www.facebook.com/wsj", "image_count": 1, "word_count": 686}, "viewport": "width=device-width, initial-scale=1.0, minimum-scale=1.0, maximum-scale=1.0, user-scalable=no", "page.section": "Article", "language": "en-US", "og": {"site_name": "WSJ", "description": "In The Wall Street Journal, Karen Ignagni writes that specialty drugs account for 25% of U.S. drug costs. Health plans need to know more about them.", "title": "Paying for the Thousand-Dollar Pill", "url": "http://www.wsj.com/articles/karen-ignagni-paying-for-the-thousand-dollar-pill-1407099169", "image": {"width": 553, "identifier": "https://si.wsj.net/public/resources/images/BN-DY408_edp080_G_20140803115310.jpg", "height": 369}, "locale": "en_US", "type": "article"}, "author": "Karen Ignagni", "article.access": "paid", "page.content.source": "WSJ Online Article", "article.origheadline": "Paying for the Thousand-Dollar Pill", "article.type": "Commentary (U.S.)", "article.id": "SB10001424052702303635604580061443794995892", "user.exp": "default", "article.updated": "2014-08-03T20:52:00.000Z"}, "_id": "\"57477af46914bd0286fd7dac\"", "article_summary": "Every day across the country, health plans are in negotiations with doctors, hospitals and device and drug manufacturers.\nLately, there has been considerable debate about the soaring prices of specialty drugs, which are...\nThe negotiations concern the prices of various treatments, with health plans aiming to make it possible for consumers to gain access to the highest-quality care at the lowest cost.\nThis interplay is fundamental to a market-based health-care system and it is vital to delivering affordable coverage options."}